Inactive Instrument

Highlights Fibrocell Science Inc Nasdaq

Equities

US3157212099

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc..	19-12-12	CI
Fibrocell Science, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-14	CI
Castle Creek Pharmaceutical Holdings, Inc. entered into a definitive agreement to acquire Fibrocell Science, Inc. for $63.3 million.	19-09-11	CI
Fibrocell Science, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-14	CI
Fibrocell Science, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB	19-05-29	CI
Fibrocell Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-15	CI
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy	19-04-15	CI
Fibrocell Science, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-27	CI
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007	19-03-27	CI
Fibrocell Science, Inc. Reports Consolidated Unaudited Earnings Results for the Nine Months Ended September 30, 2018	18-11-13	CI
Fibrocell Science, Inc. Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007	18-10-25	CI
Fibrocell Science, Inc. Announces U.S. Food and Drug Administration Granted Fast Track Designation to FCX-013	18-09-05	CI
Fibrocell Science, Inc. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018; Expects to Enroll A Total of Six Patients Ages Seven and Older by the End of the Third Quarter of 2018	18-08-09	CI
Fibrocell Science, Inc. Provides an Update on Interim Results and Progress of its Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa	18-05-21	CI
Fibrocell Science, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-10	CI
Fibrocell Science, Inc. Announces the Earnings Results for the Year Ended December 31, 2017	18-03-19	CI
Fibrocell Science, Inc. Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderm	18-03-06	CI
Fibrocell Announces Submission of Investigational New Drug Application for Fcx-013 for the Treatment of Moderate to Severe Localized Scleroderma	18-02-05	CI
Fibrocell Science, Inc. Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, PA	18-01-30	CI
Fibrocell Science, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fibrocell Science Inc Nasdaq

Equities

US3157212099

Highlights

Filters